Literature DB >> 22004601

Spot drug-eluting stenting for long coronary stenoses: long-term results of a randomized clinical study.

Demosthenes G Katritsis1, Socrates Korovesis, Efthalia Tzanalaridou, Eleftherios Giazitzoglou, Theodoros Zografos, Bernhard Meier.   

Abstract

BACKGROUND: Preliminary results of a randomized trial have suggested that total lesion coverage with drug-eluting stents (DES) is not necessary in the presence of diffuse disease of nonuniform severity. In the present study, we report long-term results of this trial.
METHODS: Consecutive, consenting patients with a long (>20 mm) coronary lesion of nonuniform severity and indication for percutaneous coronary intervention were randomized to full stent coverage of the atherosclerotic lesion with multiple, overlapping (full DES group, n = 90) or spot stenting of the hemodynamically significant parts of the lesion only (defined as diameter stenosis > 50%) (spot DES group, n = 89).
RESULTS: At a follow-up of 2-7 years, 30 patients with full DES (33.3%) and 12 patients (13.5%) with spot DES had a major adverse cardiac event (MACE) (P = 0.015). Cox proportional hazard model showed that the risk for MACE was almost 65% lower among patients who were subjected to spot DES compared to those who underwent full DES (HR = 0.35, 95% CI = 0.18-0.68, P = 0.002). This association remained significant even after controlling for age, sex, and lesion length, and the type of stent used (HR = 0.41, 95% CI = 0.20-0.81, P = 0.011).
CONCLUSIONS: In the presence of diffuse disease of nonuniform severity, selective stenting of only the significantly stenosed parts of the lesion confers better long-term results compared to total lesion coverage with DES. ©2011, Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22004601     DOI: 10.1111/j.1540-8183.2011.00662.x

Source DB:  PubMed          Journal:  J Interv Cardiol        ISSN: 0896-4327            Impact factor:   2.279


  1 in total

1.  Long-Term Predictors of Clinical Events after Off-Label Use of Drug-Eluting Stent beyond 1 Year.

Authors:  Kyeong Ho Yun; Jum Suk Ko; Sang Jae Rhee; Eun Mi Lee; Nam Jin Yoo; Nam-Ho Kim; Seok Kyu Oh; Jin-Won Jeong
Journal:  Korean Circ J       Date:  2013-03-31       Impact factor: 3.243

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.